Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5239638 | 0.98 | KDM4E (0.59) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL24581298 | 0.89 | ECE1 (0.54) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL5240216 | 0.85 | KDM4E (0.57) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL12432224 | 0.84 | IRAK4 (0.49) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2352264 | 0.83 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31591148 | 0.83 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2829475 | 0.82 | PARP1 (0.54) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2932846 | 0.82 | KCNH2 (0.55) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL7662023 | 0.82 | KDM4E (0.64) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL347912 | 0.82 | KDM4E (0.64) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| WO-2024054972-A2 | RADIONUCLIDE COMPOSITION AND METHOD OF USING SAME FOR DETECTION OF TUMOR CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023178449-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-09-28 | — | — | WO | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| EP-1355892-A1 | 2-AMINO-4-(PYRIDIN-2-YL)-THIAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062794-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062776-A1 | 2-AMINO-4-(PYRIDIN-2-YL)-THIAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| US-5169935-A | Solid phase synthesis | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-12-08 | — | — | US | disclosed |
| WO-1991019737-A1 | METHOD OF MAKING PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0084118-B1 | PROCESS FOR THE PREPARATION OF 2-HALOGEN-PYRIDINE DERIVATIVES | LONZA AG (CH) | 1986-04-09 | — | — | EP | disclosed |
| US-4556716-A | HALOGENATION OF THE 2-CARBOXYLPYRIDINE OXIDE | LONZA LTD. (CH) | 1985-12-03 | — | — | US | disclosed |
| EP-0084118-A1 | Process for the preparation of 2-halogen-pyridine derivatives | LONZA AG (CH) | 1983-07-27 | — | — | EP | disclosed |
| US-4192880-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | KANEBO, LTD. (JP) | 1980-03-11 | — | — | US | disclosed |
| US-4188486-A | 2-Substituted benzimidazole compounds | KANEBO, LTD. (JP) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | KDM4E 2583/4885ALOX15 616/4885TSHR 481/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | KDM4E 2583/4885ALOX15 616/4885TSHR 481/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | KDM4E 2583/4885ALOX15 616/4885TSHR 481/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | KDM4E 2583/4885ALOX15 616/4885TSHR 481/4885 |
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | KDM4E 1726/4885ALOX15 1877/4885TSHR 1143/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | KDM4E 946/4885ALOX15 3795/4885TSHR 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.